Angiotensin-Neprilysin Combinations Marketing Poly or Therapeutic Optimization.
Editor.
John
J
Somberg
D000613:Aminobutyrates / Q000494:pharmacology / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D002317:Cardiovascular Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004338:Drug Combinations; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D013777:Tetrazoles / Q000494:pharmacology / Q000627:therapeutic use*; D000068756:Valsartan
D000613:Aminobutyrates; D001713:Biphenyl Compounds; D002317:Cardiovascular Agents; D004338:Drug Combinations; D013777:Tetrazoles; D000068756:Valsartan; C549068:sacubitril and valsartan sodium hydrate drug combination